RT Journal Article SR Electronic T1 International multicenter examination of MOG antibody assays JF Neurology - Neuroimmunology Neuroinflammation JO Neurol Neuroimmunol Neuroinflamm FD Lippincott Williams & Wilkins SP e674 DO 10.1212/NXI.0000000000000674 VO 7 IS 2 A1 Markus Reindl A1 Kathrin Schanda A1 Mark Woodhall A1 Fiona Tea A1 Sudarshini Ramanathan A1 Jessica Sagen A1 James P. Fryer A1 John Mills A1 Bianca Teegen A1 Swantje Mindorf A1 Nora Ritter A1 Ulrike Krummrei A1 Winfried Stöcker A1 Juliane Eggert A1 Eoin P. Flanagan A1 Melanie Ramberger A1 Harald Hegen A1 Kevin Rostasy A1 Thomas Berger A1 Maria Isabel Leite A1 Jacqueline Palace A1 Sarosh R. Irani A1 Russell C. Dale A1 Christian Probst A1 Monika Probst A1 Fabienne Brilot A1 Sean J. Pittock A1 Patrick Waters YR 2020 UL http://nn.neurology.org/content/7/2/e674.abstract AB Objective To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.Methods The following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG).Results We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.Conclusions Live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.ADEM=acute disseminated encephalomyelitis; AQP4=aquaporin-4; CBA=cell-based assay; FACS=fluorescence-activated cell sorting; IF=immunofluorescence; IfQ=Institute for Quality Assurance; Ig=immunoglobulin; MOG=myelin oligodendrocyte glycoprotein; NMOSD=neuromyelitis optica spectrum disorder